Stoke Therapeutics, Inc.
STOK· Nasdaq
Released Nov 12, 2020, before the open
10-Q filed Nov 12, 2020, 43 days after period end · 0001564590-20-053586
| Metric | Q3 2020 | Q3 2019 | Q3 2018 |
|---|---|---|---|
| Net Income | -$13.68M | -$8.60M | -$3.32M |
| EPS Diluted | -$0.41 | -$0.26 | -$4.75 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Stoke Therapeutics, Inc. · CIK 1623526 · Engraved from SEC EDGAR
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
ended Sep 30, 2020 · filed Nov 12, 2020 · 43 d after period end
0.5% from the close of Nov 11, 2020 to the close of Nov 13, 2020, the first after the release.